220 related articles for article (PubMed ID: 34990570)
1. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
Naranbhai V; St Denis KJ; Lam EC; Ofoman O; Garcia-Beltran WF; Mairena CB; Bhan AK; Gainor JF; Balazs AB; Iafrate AJ;
Cancer Cell; 2022 Jan; 40(1):103-108.e2. PubMed ID: 34990570
[TBL] [Abstract][Full Text] [Related]
2. The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses.
Zhang L; Chen H; Yang S; Zhao Y; Shen X; He X; Ye H; Wang D; Lou J; Wang Y; Wu S
Front Immunol; 2022; 13():990071. PubMed ID: 36203574
[TBL] [Abstract][Full Text] [Related]
3. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
4. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.
Shapiro LC; Thakkar A; Campbell ST; Forest SK; Pradhan K; Gonzalez-Lugo JD; Quinn R; Bhagat TD; Choudhary GS; McCort M; Sica RA; Goldfinger M; Goel S; Anampa JD; Levitz D; Fromowitz A; Shah AP; Sklow C; Alfieri G; Racine A; Wolgast L; Greenberger L; Verma A; Halmos B
Cancer Cell; 2022 Jan; 40(1):3-5. PubMed ID: 34838186
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
Gonzalez Lopez Ledesma MM; Sanchez L; Ojeda DS; Oviedo Rouco S; Rossi AH; Varese A; Mazzitelli I; Pascuale CA; Miglietta EA; Rodríguez PE; Pallarés HM; Costa Navarro GS; Caramelo JJ; Rothlauf PW; Liu Z; Bloyet LM; Cornejo Pontelli M; Rasetto NB; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Bianchimano L; Ríos AS; Treffinger Cienfuegos MS; Rodriguez García DR; Longueira Y; Laufer N; Alvarez D; Ceballos A; Ochoa V; Monzani C; Turk G; Salvatori M; Carradori J; Prost K; Rima A; Varela C; Ercole R; Toro RI; Gutierrez S; Zubieta M; Acuña D; Nabaes Jodar MS; Torres C; Mojsiejczuk L; Viegas M; Velazquez P; Testa C; Kreplak N; Yanovsky M; Whelan S; Geffner J; Pifano M; Gamarnik AV
mBio; 2022 Feb; 13(1):e0344221. PubMed ID: 35073758
[TBL] [Abstract][Full Text] [Related]
7. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants.
Bates TA; McBride SK; Leier HC; Guzman G; Lyski ZL; Schoen D; Winders B; Lee JY; Lee DX; Messer WB; Curlin ME; Tafesse FG
Sci Immunol; 2022 Feb; 7(68):eabn8014. PubMed ID: 35076258
[TBL] [Abstract][Full Text] [Related]
8. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
9. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
Keeton R; Richardson SI; Moyo-Gwete T; Hermanus T; Tincho MB; Benede N; Manamela NP; Baguma R; Makhado Z; Ngomti A; Motlou T; Mennen M; Chinhoyi L; Skelem S; Maboreke H; Doolabh D; Iranzadeh A; Otter AD; Brooks T; Noursadeghi M; Moon JC; Grifoni A; Weiskopf D; Sette A; Blackburn J; Hsiao NY; Williamson C; Riou C; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Moore PL; Burgers WA
Cell Host Microbe; 2021 Nov; 29(11):1611-1619.e5. PubMed ID: 34688376
[TBL] [Abstract][Full Text] [Related]
10. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
[TBL] [Abstract][Full Text] [Related]
12. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
14. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM; Tan NH; Rietdijk WJR; Geers D; Sablerolles RSG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Rugebregt S; Goorhuis A; Postma DF; Visser LG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; Haagmans BL; van Baarle D; Koopmans MPG; ; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD
Nat Commun; 2024 May; 15(1):4224. PubMed ID: 38762522
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
16. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
[TBL] [Abstract][Full Text] [Related]
17. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
19. Antigenic Cartography of SARS-CoV-2.
Astakhova EA; Morozov AA; Vavilova JD; Filatov AV
Biochemistry (Mosc); 2024 May; 89(5):862-871. PubMed ID: 38880647
[TBL] [Abstract][Full Text] [Related]
20. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Terpos E; Trougakos IP; Gavriatopoulou M; Papassotiriou I; Sklirou AD; Ntanasis-Stathopoulos I; Papanagnou ED; Fotiou D; Kastritis E; Dimopoulos MA
Blood; 2021 Jul; 137(26):3674-3676. PubMed ID: 33861315
[No Abstract] [Full Text] [Related]
[Next] [New Search]
